These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 33880800)

  • 1. Efficacy and safety of methylphenidate on attention deficit hyperactivity disorder in children with Down syndrome.
    Roche M; Mircher C; Toulas J; Prioux E; Conte M; Ravel A; Falquero S; Labidi A; Stora S; Durand S; Mégarbané A; Cieuta-Walti C
    J Intellect Disabil Res; 2021 Aug; 65(8):795-800. PubMed ID: 33880800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methylphenidate for children and adolescents with autism spectrum disorder.
    Sturman N; Deckx L; van Driel ML
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011144. PubMed ID: 29159857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    Epstein T; Patsopoulos NA; Weiser M
    Cochrane Database Syst Rev; 2014 Sep; (9):CD005041. PubMed ID: 25230710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis.
    Rodrigues R; Lai MC; Beswick A; Gorman DA; Anagnostou E; Szatmari P; Anderson KK; Ameis SH
    J Child Psychol Psychiatry; 2021 Jun; 62(6):680-700. PubMed ID: 32845025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study.
    Santosh PJ; Baird G; Pityaratstian N; Tavare E; Gringras P
    Child Care Health Dev; 2006 Sep; 32(5):575-83. PubMed ID: 16919137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents.
    Soutullo C; Banaschewski T; Lecendreux M; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Bloomfield R; Squires LA; Coghill DR
    CNS Drugs; 2013 Sep; 27(9):743-51. PubMed ID: 23801529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of extended release methylphenidate treatment on ratings of attention-deficit/hyperactivity disorder (ADHD) and associated behavior in children with autism spectrum disorders and ADHD symptoms.
    Pearson DA; Santos CW; Aman MG; Arnold LE; Casat CD; Mansour R; Lane DM; Loveland KA; Bukstein OG; Jerger SW; Factor P; Vanwoerden S; Perez E; Cleveland LA
    J Child Adolesc Psychopharmacol; 2013 Jun; 23(5):337-51. PubMed ID: 23782128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of osmotic-release oral system (OROS) methylphenidate for mothers with attention-deficit/hyperactivity disorder (ADHD): preliminary report of effects on ADHD symptoms and parenting.
    Chronis-Tuscano A; Seymour KE; Stein MA; Jones HA; Jiles CD; Rooney ME; Conlon CJ; Efron LA; Wagner SA; Pian J; Robb AS
    J Clin Psychiatry; 2008 Dec; 69(12):1938-47. PubMed ID: 19192455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of a Long-Acting Multilayer-Release Methylphenidate Formulation (PRC-063) in the Treatment of Adolescent Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Clinical Trial with a 6-Month Open-Label Extension.
    Weiss MD; Cutler AJ; Kollins SH; Donnelly GAE
    J Child Adolesc Psychopharmacol; 2021 Nov; 31(9):610-622. PubMed ID: 34637343
    [No Abstract]   [Full Text] [Related]  

  • 10. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.
    Stein MA; Sarampote CS; Waldman ID; Robb AS; Conlon C; Pearl PL; Black DO; Seymour KE; Newcorn JH
    Pediatrics; 2003 Nov; 112(5):e404. PubMed ID: 14595084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depressive symptoms as a side effect of the sustained release form of methylphenidate in a 7-year-old boy with attention-deficit hyperactivity disorder.
    Lakić A
    Vojnosanit Pregl; 2012 Feb; 69(2):201-4. PubMed ID: 22500377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylphenidate treatment for attention-deficit/hyperactivity disorder in children and adolescents with velocardiofacial syndrome: an open-label study.
    Gothelf D; Gruber R; Presburger G; Dotan I; Brand-Gothelf A; Burg M; Inbar D; Steinberg T; Frisch A; Apter A; Weizman A
    J Clin Psychiatry; 2003 Oct; 64(10):1163-9. PubMed ID: 14658963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)].
    Golubchik P; Sever J; Weizman A
    Harefuah; 2011 Oct; 150(10):788-90, 814. PubMed ID: 22111124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of methylphenidate treatment on psychopathic behavior of patients having attention-deficit hyperactivity disorder with and without oppositional defiant disorder.
    Golubchik P; Levy T; Weizman A
    Int Clin Psychopharmacol; 2018 Nov; 33(6):330-333. PubMed ID: 29958238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder.
    Pliszka SR; Wilens TE; Bostrom S; Arnold VK; Marraffino A; Cutler AJ; López FA; DeSousa NJ; Sallee FR; Incledon B; Newcorn JH
    J Child Adolesc Psychopharmacol; 2017 Aug; 27(6):474-482. PubMed ID: 29172680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remission in children and adolescents diagnosed with attention-deficit/hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate.
    Chou WJ; Chen SJ; Chen YS; Liang HY; Lin CC; Tang CS; Huang YS; Yeh CB; Chou MC; Lin DY; Hou PH; Wu YY; Liu HJ; Huang YF; Hwang KL; Chan CH; Pan CH; Chang HL; Huang CF; Hsu JW
    J Child Adolesc Psychopharmacol; 2012 Jun; 22(3):215-25. PubMed ID: 22537358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis and Treatment Options for Preschoolers with Attention-Deficit/Hyperactivity Disorder.
    Wigal S; Chappell P; Palumbo D; Lubaczewski S; Ramaker S; Abbas R
    J Child Adolesc Psychopharmacol; 2020 Mar; 30(2):104-118. PubMed ID: 31967914
    [No Abstract]   [Full Text] [Related]  

  • 19. High pretreatment cognitive impulsivity predicts response of oppositional symptoms to methylphenidate in patients with attention-deficit hyperactivity disorder/oppositional defiant disorder.
    Golubchik P; Shalev L; Tsamir D; Manor I; Weizman A
    Int Clin Psychopharmacol; 2019 May; 34(3):138-142. PubMed ID: 30640748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Supervised off-label prescribing of methylphenidate in adult ADHD].
    Carton L; Dondaine T; Deheul S; Marquié C; Brigadeau F; Amad A; Devos D; Danel T; Bordet R; Cottencin O; Gautier S; Ménard O
    Encephale; 2019 Feb; 45(1):74-81. PubMed ID: 30122296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.